Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Sprout Health vs LifeRx.md

Two GLP-1 desks, one scoreboard. We put Sprout Health and LifeRx.md head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 6 · Grade B

Sprout Health

Visit Sprout Health Full brief →
vs
No. 106 · Grade C

LifeRx.md

Visit LifeRx.md Full brief →

The verdict

Sprout Health takes this head-to-head.

Sprout Health scores 86 to 72 on our six-factor Brief Score — A LegitScript-certified desk that pairs low-cost compounded semaglutide and tirzepatide with a real brand-name Wegovy and Zepbound path — and a near-frictionless, often visit-free start.

That doesn't make LifeRx.md a bad call — it's best for readers who want budget patients wanting flat, dose-independent compounded glp-1 pricing nationwide. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
90
78
Supply Reliability
82
75
Transparency
88
48
Access Breadth
92
90
Clinical Oversight
78
71
Track Record
84
73
Sprout HealthBrief Score 86 · 72LifeRx.md

Price, coverage & the tracker

Sprout HealthLifeRx.md
Brief Score86/100 (B)72/100 (C)
Semaglutide$149/mo$200/mo
Tirzepatide$199/mo$275/mo
CoverageNot disclosedAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

Sprout Health: Compounded $149 semaglutide / $199 tirzepatide held flat this cycle, with a brand-name Wegovy/Zepbound path available on the same account.

LifeRx.md: New to the tracker on 1 August 2026. The published line reads $200/mo at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.